Is vedolizumab effective for the treatment of Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print
Answer

Vedolizumab, another integrin antagonist, is approved for Crohn disease and ulcerative colitis. It is specific for α4β7 integrin. Approval was based on a large phase 3 clinical trial conducted to simultaneously evaluate vedolizumab for both UC and CD that included several clinical studies involving 2,700 patients in nearly 40 countries.

Among patients with CD who had a response to induction therapy with vedolizumab, 39.0% of those assigned to vedolizumab every 8 weeks were in clinical remission at week 52, compared with 21.6% assigned to placebo (P< 0.001). [112]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!